



MEDISTEP HEALTHCARE LIMITED

CIN- U21009GJ2023PLC141841

Regd. Off: 05,S.NO-245/B,PLOT-19,T.PNR.A-ONE HOTEL, N.H.-8,NA, Narol,
Ahmedabad, Ahmadabad City, Gujarat, India, 382405

Website: <http://medistepphc.com>

Email: medistephealthcare.ltd@gmail.com

Mo: 8460768695

Date: 30.05.2026

To,
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor |
Plot No. C/1, G Block Bandra - Kurla Complex
Bandra (E), Mumbai – 400051

Symbol: MEDISTEP
ISIN: INE0UOY01019

Subject: Outcome of the Board Meeting under Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Board of Directors of Medistep Healthcare Limited at their meeting held on **Saturday, 30th May, 2026** at the Registered Office of the Company situated at 05, S.No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, NR. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad, Daskroi, Gujarat-382405 has inter alia, considered and approved the Standalone Audited Financial Results of the Company for the half year and year ended 31st March 2026.

We enclose herewith a copy of the said Financial Results along with the Auditor's Report by the Statutory Auditors of the Company.

The meeting of Board of Directors commenced at 12:10 P.M. and concluded at 01:40 P.M.

You are requested to take the same on your record.

Thanking you,
Yours faithfully,

**For and on behalf of
Medistep Healthcare Limited**

**Girdhari Lal Prajapat
Managing Director
DIN: 09513249**

Encl. as above



MEDISTEP HEALTHCARE LIMITED

CIN- U21009GJ2023PLC141841

Regd. Off: 05,S.NO-245/B,PLOT-19,T.PNR.A-ONE HOTEL, N.H.-8,NA, Narol,
Ahmedabad, Ahmadabad City, Gujarat, India, 382405

Website: <http://medistepphc.com>

Email: medistephealthcare.ltd@gmail.com

Mo: 8460768695

To,
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor |
Plot No. C/1, G Block Bandra - Kurla Complex
Bandra (E), Mumbai – 400051

Symbol: MEDISTEP
ISIN: INE0UOY01019

Subject: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016

Dear Sir/Madam,

We, Medistep Healthcare Limited, a public limited Company having its registered office at 05, S. No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, NR. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad, Daskroi, Gujarat-382405, hereby declares that Statutory Auditor of the Company has issued unmodified opinion on Standalone Annual Audited Financial Results for the year ended on 31st March, 2026.

Yours Faithfully,

For and on behalf of
Medistep Healthcare Limited

Girdhari Lal Prajapat
Managing Director
DIN: 09513249



MUKESH MISHRA & CO. CHARTERED ACCOUNTANTS

Independent Auditors' Report on Standalone Financial Results of Medistep Healthcare Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors
Medistep Healthcare Limited

We have audited the accompanying Statement of Standalone Financial Results of **Medistep Healthcare Limited** ("the Company") for the year ended March 31, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- b. gives a true and fair view in conformity with applicable Indian accounting standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the Standalone Financial Results.

Management's and Board of Director's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Standalone Financial Statements. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with Indian accounting standards prescribed under section 133 of the Act, read



with relevant law issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulation, as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticisms throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.



- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The financial statement includes the results for the six months ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of September of the current financial year which were subject to limited review by us, as required under the LODR Regulations. Our opinion on the Audit of the Standalone Financial Results for the year ended 31st March, 2026 is not modified in respect of this matter.

For Mukesh Mishra & Co

Chartered Accountants

FRN: 016888C



Bhoomika Nowlakha

Partner

Membership No.: 431509

Date: May 30, 2026

Place: Ahmedabad

UDIN: 26431509CJXZNZ7536



MUKESH MISHRA & CO. CHARTERED ACCOUNTANTS

UTILIZATION OF IPO PROCEEDS CERTIFICATE


To
The Board of Directors
Medistep Healthcare Limited
R/O-05, S. No-245/B, Plot-19,
T.P.S. 56, Free Trade Center, Nr. A-One Hotel,
N.H.-8, Narol, Ahmedabad, Gujarat- 382405

Based upon an independent verification of facts and figures received from **M/s Medistep Healthcare Limited**, a Company incorporated under the provisions of the Companies Act, 2013 and presently having its registered office at 05, S. No-245/B, Plot-19, T.P.S. 56, Free Trade Center, Nr. A-One Hotel, N.H.-8, Narol, Ahmedabad, Gujarat- 382405 and bearing CIN: U21009GJ2023PLC141841 ("the Company"), we hereby certify that the Company has utilized IPO proceeds aggregating to INR 1,559.17 Lakhs. The details of the utilization of IPO proceeds as on 31 March 2026 as per the certificate are as follows:

(Rs. In Lakhs)

S No.	Object of the Issue	Amount allotted for the object	Amount utilized till 31st March 2026	Amount unutilized till 31st March 2026	Deviation (if any)
a	Capital Expenditure Requirement	50.75	-	50.75	-
b	Working Capital Requirement	1,234.17	1,234.17	-	-
c	General corporate purpose	164.01	164.01	-	-
d	Public issue related expenses	160.99	160.99	-	-
Total		1,609.92	1,559.17	50.75	-

For Mukesh Mishra & Co,
Chartered Accountants,
Firm Registration No: 016868C


Bhoomika Nowlakha
Partner
Membership No: 431509
UDIN: 26431509WUJFPR9486
Date: May 30, 2026
Place: Ahmedabad

Medistep Healthcare Limited

CIN: U21009GJ2023PLC141841

Regd. Office : 05, S.No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol,
Ahmedabad, Daskroi, Gujarat, India, 382405

Website: www.medistephc.com Email: Info@medistephc.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH, 2026

Rs. In Lakhs

Sl.No	Particulars	Six months ended			Year ended	
		31-03-2026	30-09-2025	31-03-2025	31.03.2026	31.03.2024
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income					
	a) Revenue from operations	3,576.22	3,506.88	2,840.32	7,083.10	4,965.48
	b) Other income	2.09	0.16	0.16	2.26	0.37
	Total income	3,578.32	3,507.04	2,840.47	7,085.36	4,965.86
2	Expenses					
	a) Purchase of stock in trade	3,083.51	2,591.75	2,055.75	5,675.26	3,533.60
	b) Cost of material consumed	277.76	714.56	439.51	992.32	842.59
	c) (Increase)/decrease in the inventories of work in progress & finished goods	(242.84)	(242.21)	(13.21)	(485.05)	(20.47)
	d) Employee benefits expense	11.33	12.63	13.42	23.97	24.97
	e) Finance cost	24.53	0.32	0.64	24.85	3.03
	f) Depreciation and amortisation expense	1.35	1.34	1.66	2.69	3.32
	g) Other expenses	20.15	31.64	14.55	51.79	25.05
	Total expenses	3,175.80	3,110.03	2,512.31	6,285.83	4,412.09
3	Profit/(loss) before exceptional item & tax (1-2)	402.52	397.01	328.16	799.53	553.77
4	Exceptional Items	-	-	-	-	-
5	Profit/(loss) before tax (3-4)	402.52	397.01	328.16	799.53	553.77
6	Tax expense	101.31	99.92	82.59	201.23	139.37
7	Net Profit/(Loss) after tax (5-6)	301.21	297.09	245.57	598.30	414.40
8	Paid-up Equity Share Capital (Face value of Rs.10/- each)	142.10	142.10	104.66	142.10	104.66
9	Other Equity (excluding revaluation reserve)	-	-	-	2,361.51	688.66
10	Earnings per share (of Rs.10/- each) Basic & Diluted (Rs.)	2.12	2.61	2.38	4.68	4.01

Notes:-

- 1 The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 30th May, 2026.
- 2 The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The results for the year ended March 31, 2026 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


As per the Accounting Standard - 17 on "Segment Reporting", the Company is primary engaged in a single business activity, and its operations are confined within India. Hence, there are no separate reportable business or geographical segments requiring disclosure in the financial statements.
The Company presents Standalone Financial Results, as it does not have any Subsidiary, Associate, or joint Venture as on March 31, 2026.
- 5 The company has issued 37,44,000 equity shares of Rs 10 each at a premium of Rs 33 each as fresh issue by way of public issue and get listed on EMERGE Platform of National Stock Exchange of India Limited on August 18, 2025. The Company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

Rs. In Lakhs

S No.	Object of the Issue	Amount allotted for the object	Amount utilized till 31st March 2026	Amount unutilized till 31st March 2026	Deviation (if any)
a	Capital Expenditure Requirement	50.75	-	50.75	-
b	Working Capital Requirement	1,234.17	1,234.17	-	-
c	General corporate purpose	164.01	164.01	-	-
d	Public issue related expenses	160.99	160.99	-	-
Total		1,609.92	1,559.17	50.75	-

- 6 The figures for the previous period/year have been regrouped / rearranged / reclassified wherever necessary.

For and on Behalf of
Medistep Healthcare Limited


Girdhari Lal Prajapat
Managing Director
DIN: 09513249
Date: May 30, 2026
Place: Ahmedabad



Medistep Healthcare Limited

CIN: U21009GJ2023PLC141841

Regd. Office : 05, S.No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad, Daskroi, Gujarat,
India, 382405

Website: www.medistephc.com Email: Info@medistephc.com

STATEMENT OF STANDALONE ASSETS & LIABILITIES AS AT MARCH 31, 2026

Rs. In Lakhs

Particulars	Standalone	
	As at 31.03.2026	As at 31.03.2025
EQUITY AND LIABILITIES		
1 Shareholders' funds		
a) Share capital	1,420.95	1,046.55
b) Reserves and surplus	2,361.51	688.66
	3,782.46	1,735.22
2 Non-current liabilities		
a) Long-term provisions	2.46	2.22
	2.46	2.22
3 Current liabilities		
a) Short-Term Borrowings	518.13	63.53
b) Trade payables		
(i) Total outstanding dues of micro enterprises and small enterprises; and	-	-
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	364.99	245.28
c) Other current liabilities	19.24	14.03
d) Short-term provisions	342.43	239.80
	1,244.79	562.64
Total	5,029.71	2,300.08
Assets		
1 Non-current assets		
a) Property, plant and equipment		
(i) Property, plant and equipment	12.19	13.97
b) Deferred tax assets (Net)	0.90	0.71
c) Non-current investment	-	0.15
d) Other non-current assets	0.65	0.65
	13.75	15.48
2 Current assets		
a) Inventories	618.21	109.54
b) Trade receivables	3,938.59	2,011.49
c) Cash and bank balances	61.30	131.01
d) Short-term loans and advances	31.81	24.85
e) Other current assets	366.05	7.71
	5,015.97	2,284.60
Total	5,029.71	2,300.08

For and on Behalf of
Medistep Healthcare Limited



Girdhari Lal Prajapat
Managing Director

DIN: 09513249

Date: May 30, 2026

Place: Ahmedabad



Medistep Healthcare Limited

CIN: U21009GJ2023PLC141841

Regd. Office : 05, S.No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad, Daskroi,
Gujarat, India, 382405

Website: www.medistephc.com Email: Info@medistephc.com

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2026

Rs. In Lakhs

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
A. Cash flow from operating activities		
Profit/(loss) before tax	799.53	553.77
Adjustments for :		
Depreciation and amortisation expense	2.69	3.32
Interest expenses	24.85	3.03
Provision for long term employee benefits	0.24	1.56
Profit on Sales of Shares	(0.10)	-
	827.21	561.66
Changes in assets and liabilities		
Decrease /(Increase) in Inventories	(508.66)	(16.67)
Decrease / (Increase) in Trade Receivable	(1,927.10)	(636.40)
Decrease / (Increase) in Long Term Loans and Advances	-	-
Decrease / (Increase) in Short Term Loans and Advances	(6.97)	(16.09)
Decrease / (Increase) in Other Assets	(358.34)	(7.81)
Increase / (Decrease) in Trade Payables	119.72	104.32
Increase / (Decrease) in Short Term Provisions	0.39	1.23
Increase / (Decrease) in Long Term Provisions	-	-
Increase / (Decrease) in Other Liabilities	5.21	12.14
Cash (used) /generated from operations	(1,848.57)	2.38
Taxes paid (net of refunds)	(99.17)	(0.25)
Net cash (used in)/from operating activities (A)	(1,947.74)	2.13
B. Cash Flow from Investing Activities		
Purchase of property, plant and equipment	(0.91)	-
Investment made	0.25	-
Net cash generated from/(used in) investing activities (B)	(0.66)	-
C. Cash flows from financing activities		
Interest & Finance Cost	(24.85)	(3.03)
Proceeds from issues of equity shares (net of issue expenses)	1,448.93	100.00
(Repayments) / proceeds of long term borrowings	-	-
(Repayments) / proceeds of short term borrowings (net)	454.61	30.93
Net cash generated from/(used in) financing activities (C)	1,878.69	127.90
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(69.71)	130.03
Cash and cash equivalents at the beginning of the year	131.01	0.97
Cash and cash equivalents at the end of the year	61.30	131.01
Cash and cash equivalents comprise of:		
Cash on hand	5.09	2.18
Balance with banks		
- in current accounts	56.21	0.02
Cheque in Hand		128.81
Total	61.30	131.01

For and on Behalf of
Medistep Healthcare Limited


Girdhari Lal Prajapat
Managing Director
DIN: 09513249
Date: May 30, 2026
Place: Ahmedabad

